GRCE
Grace Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.10
−1.87%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$0.15
- Revenue estimate
- $1.0M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.91
- EPS estimate
- -$0.13
- Revenue actual
- —
- Revenue estimate
- $400.0K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 7
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -153.4%
- Revenue beats (12Q)
- —
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026